Drug Trial Radar · NCT02413346
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
Last checked: Nov 20, 2026Latest source record: Feb 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
490
Actual
Start
Mar 20, 2015
Primary completion
Aug 26, 2016
Study completion Aug 26, 2016
Sponsor
- Lead sponsor
- Almirall, S.A.Industry
- Sponsor type
- Industry
- Collaborators
- Allergan
- First posted
- Apr 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral sarecycline in the long-term treatment of participants with moderate to severe facial acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
SarecyclineDrug
Administered based on participant's body weight.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE)Time frame: Up to 40 Weeks
Locations
56 sites in 1 country. Site status is shown where the registry gives one.
Actavis Investigational Study Site #206
Mobile, Alabama
Actavis Investigational Study Site #236
Hot Springs, Arkansas
Actavis Investigational Study Site #245
Carlsbad, California
Actavis Investigational Study Site #129
Encino, California
Actavis Investigational Study Site #209
Fremont, California
Actavis Investigational Study Site #147
Sacramento, California
Actavis Investigational Study Site #150
San Diego, California
Actavis Investigational Study Site #125
San Diego, California
Actavis Investigational Study Site #204
San Diego, California
Actavis Investigational Study Site #222
Denver, Colorado
Actavis Investigational Study Site #148
Wheat Ridge, Colorado
Actavis Investigational Study Site #226
Clearwater, Florida
Actavis Investigational Study Site #238
Jupiter, Florida
Actavis Investigational Study Site #249
Miami, Florida
Actavis Investigational Study Site #145
Miami, Florida
Actavis Investigational Study Site #211
Miramar, Florida
Actavis Investigation Study Site # 140
North Miami Beach, Florida
Actavis Investigational Study Site #151
Orange, Florida
Actavis Investigational Study Site #203
Tampa, Florida
Actavis Investigational Study Site #242
Snellville, Georgia
Actavis Investigational Study Site #124
Boise, Idaho
Actavis Investigational Study Site #106
Chicago, Illinois
Actavis Investigational Study Site #113
South Bend, Indiana
Actavis Investigational Study Site #213
Louisville, Kentucky
Actavis Investigational Study Site #217
Rockville, Maryland
Actavis Investigational Study Site #251
Clarkston, Michigan
Actavis Investigational Study Site #235
Clinton Township, Michigan
Actavis Investigational Study Site #227
Fort Gratiot, Michigan
Actavis Investigational Study Site #111
Warren, Michigan
Actavis Investigational Study Site #221
Fridley, Minnesota
Actavis Investigational Study Site #231
Omaha, Nebraska
Actavis Investigational Study Site #146
New York, New York
Actavis Investigational Study Site #208
New York, New York
Actavis Investigational Study Site #240
Rochester, New York
Actavis Investigational Study Site #230
Stony Brook, New York
Actavis Investigational Study Site #229
Raleigh, North Carolina
Actavis Investigational Study Site #149
Gresham, Oregon
Actavis Investigational Study Site #257
Philadelphia, Pennsylvania
Actavis Investigational Study Site #225
Goodlettsville, Tennessee
Actavis Investigational Study Site #128
Knoxville, Tennessee
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.